In one paragraphArticle in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
39 authors.
Kie Kyon Huang *Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-4104-8951 Takeshi Hagihara *Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0007-9263-1553 Benedict Shi Xiang LianProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-3467-5394 Shen Kiat LimProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-4464-3609 Roxanne Hui Heng ChongDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-7640-2052 Supriya SrivastavaDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-6727-3076 Jason Xing KangLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.ORCID 0000-0002-8072-015X May Yin LeeGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.ORCID 0000-0003-2366-9463 Angie Lay-Keng TanProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-8238-0515 Shamaine Wei Ting HoGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.ORCID 0000-0002-2595-0710 Siti Aishah Binte Abdul GhaniProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-2317-0179 Clara Shi Ya NgProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0000-2090-1955 Lin LiuDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0009-0003-4351-3201 Feng ZhuDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0001-6030-9251 Tiing Leong AngDepartment of Gastroenterology & Hepatology, Changi General Hospital, Singapore, Singapore.ORCID 0000-0001-9993-8549 Robert J HuangDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-0891-7409 Christopher J L KhorProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-1409-5691 Hyun-Soo KimDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Seoul, Korea.ORCID 0000-0001-7190-0362 Louis Ho Shing LauDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.ORCID 0000-0002-4163-4531 Yi-Chia LeeDepartment of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-8160-1216 Ming TehDepartment of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0001-6879-8678 Mann Yie ThianDepartment of Gastroenterology & Hepatology, Tan Tock Seng Hospital, Singapore, Singapore.ORCID 0009-0001-6495-2938 Wai Leong TamGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.ORCID 0000-0003-2365-5264 Xin LuLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-6587-1152 Sunny H WongLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.ORCID 0000-0002-3354-9310 Jimmy B Y SoDepartment of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-9772-7905 Hyunsoo ChungDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0001-5159-357X Jonathan LeeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0001-7065-8041 Khay Guan YeohDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-7802-4606 Funding
Agency for Science, Technology and Research (A*STAR)Cancer Science Institute of Singapore, National University of Singapore (CSI)Duke-NUS Medical School (DukeNUS)Ministry of Education - Singapore (MOE) MOE-MOET32021-0004National Medical Research Council (NMRC) MOH-000967National Research Foundation Singapore (NRF) MOH-OFLCG18May-0003National University of Singapore (NUS) NUHSRO/2022/071/NUSMed/Microbiome/LOA
6 · The paper itselfAbstract
Intestinal metaplasia (IM) is a premalignant condition associated with increased risk of gastric cancer-a deadly malignancy with varying geographic incidence. High-depth targeted sequencing of more than 1,500 IM samples from six countries identified 47 significantly mutated genes, including driver genes associated with high-risk populations and worse prognosis (ARID1A), KRAS/MAPK signaling (KRAS, BRAF, MAP2K1, MAP3K1, and MAP2K4), and altered mucosal immunity (PIGR). IM whole-genome sequencing and DNA methylation analysis revealed SBS17 as a specific mutational signature separating IMs from normal gastric tissues, associated with late DNA replication, genomic hypomethylation, and tobacco exposure. Beyond epithelial-derived somatic mutations, we observed elevated clonal hematopoiesis (CH) in patients with IM associated with age, smoking, and enhanced risk of progressing to gastric cancer. Patients with CH expansions exhibited co-occurring IM PIGR truncating mutations and greater colonization of the IM microenvironment by orally derived bacteria, suggesting that CH may promote IM progression by modulating host-microbe mucosal immunity. SIGNIFICANCE: This international study identifies recurrent IM driver genes, IM-specific mutational signatures, and alterations in IM-associated immune landscapes and microbiomes. Our results highlight a role for nonepithelial somatic alterations (CH) in IM progression to gastric cancer, offering new translational opportunities for early cancer detection and interception.
Indexed as
Clonal HematopoiesisMutationPrecancerous ConditionsStomach NeoplasmsFemaleHumansIncidenceMetaplasia
Identifiers
PMID41532847
PMCPMC13056296
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390